Safety study of oral dersimelagon for erythropoietic porphyria
Part of Blood & lymphatic, Genetic & congenital, Skin clinical trials.
This trial checks the long-term safety and side effects of an oral medicine called dersimelagon in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). It is mainly for people who have already finished an earlier dersimelagon study and are able to keep coming to clinic visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already completed a prior dersimelagon study visit schedule (ending around Week 58 or later, per the study plan).
- You must be able and willing to travel to the study sites for all scheduled visits.
- You must sign consent (and for teens, get both teen agreement and parent permission).
- If you can become pregnant: you must have a negative urine pregnancy test before the first dose and use 2 effective contraception methods during the study.
- You must not have EPP/XLP caused by other skin conditions (no other photodermatoses besides EPP/XLP).
- You must not have serious liver problems, and blood tests must be below certain limits (AST/ALT/ALP and bilirubin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how safe and well bitopertin works over the long term for people with EPP. It mainly includes people who already finished an earlier bitopertin study, to keep tracking side effects and overall progress.
This program provides access to bitopertin, an experimental medicine being tested for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)—rare genetic conditions affecting how your body processes heme, a component of blood. The program aims to offer the medication to eligible patients while safety is being studied.
This study tracks how your body reacts to sunlight if you have erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP)—rare genetic conditions that cause painful skin reactions to sun exposure. Researchers will use special devices and daily logs to better understand your symptoms and how light affects your skin.
This trial tests an oral medication called ciclopirox (ATL-001) to see if it can reduce skin sensitivity to sunlight in adults with CEP. It aims to improve the skin lesions caused by this rare disease.
This study tests a new erythropoietin (a medicine that helps your body make red blood cells) and compares it to an approved version called Eprex. It is for healthy adults to see how the two medicines work in the body and if they are safe.
This study is testing the long-term safety of an investigational migraine medication called elismetrep. It is for people who have already completed a previous study of this drug and are willing to continue using a smartphone app to track their symptoms daily.
Hear when a new EPP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.